Innate Pharma announces revenue for the first nine months of 2012 and updates on its cash position
Innate Pharma to meet its retail investors at Actionaria on November 23 & 24
First clinical trial with IPH2102/BMS-986015 sponsored by Bristol-Myers Squibb announced
Results of IPH2101 Phase I trial in AML published in BLOOD
Financial results for the first half of 2012
Innate Pharma receives regulatory authorization to start randomized Phase II trial with IPH2102 in Acute Myeloid Leukemia
Signing of a liquidity contract with GILBERT DUPONT, ending of the previous liquidity contract with NATIXIS SECURITIES
Number of shares and voting rights of Innate Pharma as at July 1, 2012
All proposed resolutions at the Annual General Meeting of June 28, 2012 were voted according to management’s recommendations
Innate Pharma to hold its Annual General Meeting of Shareholders on June 28, 2012, in Marseilles, France
